Ascendis Pharma A (ASND) Other Non-Current Liabilities (2019 - 2026)

Ascendis Pharma A has disclosed Other Non-Current Liabilities across 8 years of filings, most recently posting $67.1 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $67.1 million, up 67.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.1 million (up 67.6% YoY), and the FY2025 annual result was $67.8 million, down 6.7% from the prior year.
• Other Non-Current Liabilities came in at $67.1 million for Q1 2026 at Ascendis Pharma A, down from $67.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $72.6 million in Q4 2024 to a low of $14.1 million in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $36.6 million (2023), against an average of $39.2 million.
• Across the five-year window, Other Non-Current Liabilities fell 6.7% in 2025 and surged 67.6% in 2026, its largest moves.
• Ascendis Pharma A's Other Non-Current Liabilities stood at $32.6 million in 2022, then jumped by 35.75% to $44.3 million in 2023, then jumped by 63.91% to $72.6 million in 2024, then slipped by 6.7% to $67.8 million in 2025, then declined by 0.96% to $67.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $67.1 million (Q1 2026), $67.8 million (Q4 2025), and $56.5 million (Q3 2025), per Business Quant data.